Utilizing Liposomal Quercetin and Gallic Acid in Localized Treatment of Vaginal Candida Infections
- PMID: 31861805
- PMCID: PMC7023398
- DOI: 10.3390/pharmaceutics12010009
Utilizing Liposomal Quercetin and Gallic Acid in Localized Treatment of Vaginal Candida Infections
Abstract
Vulvovaginal candidiasis (VVC) is a widely spread fungal infection that causes itching, pain and inflammation at the vaginal site. Although common, currently available treatment suffers from limited efficacy and high recurrence. In addition, the growing problem of resistance to azole drugs used in current treatments emphasizes the need for superior treatment options. Antimicrobial polyphenols are an attractive approach offering multitargeting therapy. We aimed to develop novel liposomes for simultaneous delivery of two polyphenols (quercetin, Q, and gallic acid, GA) that, when released within the vaginal cavity, act in synergy to eradicate infection while alleviating the symptoms of VVC. Q was selected for its anti-itching and anti-inflammatory properties, while GA for its reported activity against Candida. Novel liposomes containing only Q (LP-Q), only GA (LP-GA) or both polyphenols (LP-Q+GA) were in the size range around 200 nm. Q was efficiently entrapped in both LP-Q and in LP-Q+GA (85%) while the entrapment of GA was higher in LP-Q+GA (30%) than in LP-GA (25%). Liposomes, especially LP-Q+GA, promoted sustained release of both polyphenols. Q and GA acted in synergy, increasing the antioxidant activities of a single polyphenol. Polyphenol-liposomes were not cytotoxic and displayed stronger anti-inflammatory effects than free polyphenols. Finally, LP-GA and LP-Q+GA considerably reduced C. albicans growth.
Keywords: Candida; gallic acid; liposomes; polyphenols; quercetin; vaginal infection.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Similar articles
-
Lactobacillus crispatus BC1 Biosurfactant Delivered by Hyalurosomes: An Advanced Strategy to Counteract Candida Biofilm.Antibiotics (Basel). 2021 Jan 1;10(1):33. doi: 10.3390/antibiotics10010033. Antibiotics (Basel). 2021. PMID: 33401413 Free PMC article.
-
Chitosan and liposomal delivery systems for epicatechin or propyl gallate targeting localized treatment of vulvovaginal candidiasis.Int J Pharm. 2024 Sep 5;662:124489. doi: 10.1016/j.ijpharm.2024.124489. Epub 2024 Jul 18. Int J Pharm. 2024. PMID: 39032871
-
Localized Therapy of Vaginal Infections and Inflammation: Liposomes-In-Hydrogel Delivery System for Polyphenols.Pharmaceutics. 2019 Jan 27;11(2):53. doi: 10.3390/pharmaceutics11020053. Pharmaceutics. 2019. PMID: 30691199 Free PMC article.
-
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.Expert Opin Pharmacother. 2018 Jun;19(9):971-977. doi: 10.1080/14656566.2018.1476490. Epub 2018 Jun 22. Expert Opin Pharmacother. 2018. PMID: 29932786 Review.
-
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors.Crit Rev Microbiol. 2016 Nov;42(6):905-27. doi: 10.3109/1040841X.2015.1091805. Epub 2015 Dec 21. Crit Rev Microbiol. 2016. PMID: 26690853 Review.
Cited by
-
Formation of a traditional Chinese medicine self-assembly nanostrategy and its application in cancer: a promising treatment.Chin Med. 2023 Jun 6;18(1):66. doi: 10.1186/s13020-023-00764-2. Chin Med. 2023. PMID: 37280646 Free PMC article. Review.
-
A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.Int J Mol Sci. 2024 Nov 11;25(22):12091. doi: 10.3390/ijms252212091. Int J Mol Sci. 2024. PMID: 39596162 Free PMC article.
-
Lecithin and Chitosan as Building Blocks in Anti-Candida Clotrimazole Nanoparticles.Pharmaceuticals (Basel). 2023 May 25;16(6):790. doi: 10.3390/ph16060790. Pharmaceuticals (Basel). 2023. PMID: 37375738 Free PMC article.
-
Toxicity Assessment of Resveratrol Liposomes-in-Hydrogel Delivery System by EpiVaginalTM Tissue Model.Pharmaceutics. 2022 Jun 17;14(6):1295. doi: 10.3390/pharmaceutics14061295. Pharmaceutics. 2022. PMID: 35745867 Free PMC article.
-
Lactobacillus crispatus BC1 Biosurfactant Delivered by Hyalurosomes: An Advanced Strategy to Counteract Candida Biofilm.Antibiotics (Basel). 2021 Jan 1;10(1):33. doi: 10.3390/antibiotics10010033. Antibiotics (Basel). 2021. PMID: 33401413 Free PMC article.
References
-
- Ahangari F., Farshbaf-khalili A., Javadzadeh Y., Adibpour M., Oskouei B.S. Comparing the effectiveness of Salvia officinalis, clotrimazole and their combination on vulvovaginal candidiasis: A randomized, controlled clinical trial. J. Obstet. Gynaecol. Res. 2019;45:897–907. doi: 10.1111/jog.13918. - DOI - PubMed
-
- Richardson J.P., Willems H.M.E., Moyes D.L., Shoaie S., Barker K.S., Tan S.L., Palmer G.E., Hube B., Naglik J.R., Peters M. Candidalysin drives epithelial signaling, neutrophil recruitment, and immunopathology at the vaginal mucosa. Infect. Immun. 2018;86:e00645-17. doi: 10.1128/IAI.00645-17. - DOI - PMC - PubMed
-
- Fidel P.L.J., Barousse M., Espinosa T., Ficarra M., Sturtevant J., Martin D.H., Quayle A.J., Dunlap K. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect. Immun. 2004;72:2939–2946. doi: 10.1128/IAI.72.5.2939-2946.2004. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources